Tissue markers for early diagnosis of pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study looks at tissue samples from people having surgery for a suspected pancreatic growth to find markers that might help diagnose pancreatic cancer earlier. By studying the removed tissue, researchers hope to learn more about the earliest changes that lead to cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You are scheduled to have surgery to remove a suspected pancreatic growth.
- After surgery, a sample of the removed tissue will be checked for specific types of growths: IPMN, PanIN, or pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer).
- There must be some leftover tissue from your surgery that can be used for research.
- You must sign a consent form allowing your tissue samples to be used in this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to analyze tiny samples of pancreatic tissue taken during a biopsy to better detect cancer. The method uses special technology to examine the physical properties of cells, which may help doctors diagnose pancreatic cancer more accurately.
This trial studies whether blood markers can help predict which pancreatic IPMNs are likely to become cancerous. If successful, it could help doctors decide when surgery is needed.
This study looks at tissue removed during surgery for pancreatic cancer to learn how cancer spreads along nerves. The goal is to find new ways to treat it.
This study checks if a simple blood test can find tiny bits of cancer DNA after your pancreatic surgery, which may help detect if cancer comes back earlier than scans. By joining, you'll help doctors learn how to better monitor the disease and guide future treatments.
This study looks at “biomarkers” (test signals in tissue or blood) in people with pancreatic cancer. It may help researchers understand the disease better and find ways to predict or track it.
This study looks at “tumor regulatory molecules,” which are substances that may be released by cancer, to improve early pancreatic cancer detection. You may join if you have early, localized pancreatic cancer that can be treated with surgery, or certain pancreatic cysts/fluid collections where doctors are investigating further.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.